Hong Kong, 29 June 2018 - CSPC Pharmaceutical Group Limited ("CSPC" or "the company", HKEx.: 01093) is pleased to announce that the company was recognized as a "Most Honored Company" again in Institutional Investor's annual All-Asia Executive Team survey, and was ranked Top 3 for all the 7 categories in the Health Care & Pharmaceuticals sector, including "Best CEO".
"2018 All-Asia Executive Team" was held once a year for the recognition of outstanding companies and executive teams. This year, a record total of 3,538 buy-side individuals and 982 sell-side analysts participated in the survey.
CSPC and its executive team stood out among 2,368 companies being nominated across 18 industries and got all the top 3 rankings in all of the 7 categories in the Health Care & Pharmaceuticals sector. Amongst all, the chairman / CEO of the company, Mr. CAI Dong-chen captured first place in "Best CEO" in all sell-side, buy-side and overall rankings.
The followings are the nominations and recognitions that CSPC achieved in "Health Care & Pharmaceuticals" sector:
- 1. Best CEO - Mr. CAI Dong-chen (First Place)
- 2. Best CFO - Mr. Eddie Chak (Second Place)
- 3. Best IR Professional - Ms. Winnie Yam (Second Place)
- 4. Best IR Program - CSPC Pharmaceutical Group Limited (First Place)
- 5. Best Corporate Governance - CSPC Pharmaceutical Group Limited (First Place)
- 6. Best ESG SRI Metrics - CSPC Pharmaceutical Group Limited (First Place)
- 7. Best Analyst Day - CSPC Pharmaceutical Group Limited (First Place)